Robert L Redner
Overview
Explore the profile of Robert L Redner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quann K, Lontos K, Sehgal A, Raptis A, Im A, Redner R, et al.
Haematologica
. 2024 Aug;
109(12):4106-4111.
PMID: 39113675
No abstract available.
2.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
3.
Im A, Quann K, Agha M, Raptis A, Redner R, Hou J, et al.
Am J Hematol
. 2024 Jan;
99(3):380-386.
PMID: 38258329
Acute myeloid leukemia (AML) in older patients has a poor prognosis, low complete remission (CR) rates, and poor overall survival (OS). Preclinical studies have shown synergistic effects of epigenetic priming...
4.
Duong V, Ruppert A, Mims A, Borate U, Stein E, Baer M, et al.
Cancer
. 2023 Apr;
129(15):2308-2320.
PMID: 37078412
Background: Patients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors...
5.
Lontos K, Tsagianni A, Agha M, Raptis A, Hou J, Farah R, et al.
Leuk Lymphoma
. 2023 Feb;
64(3):750-752.
PMID: 36722791
No abstract available.
6.
Lontos K, Tsagianni A, Agha M, Raptis A, Hou J, Farah R, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3257-3260.
PMID: 36075047
No abstract available.
7.
McKeown C, Ricciuti A, Agha M, Raptis A, Hou J, Farah R, et al.
Support Care Cancer
. 2021 Sep;
30(2):1673-1679.
PMID: 34562168
Purpose: Central venous catheters (CVCs) are widely used in acute myeloid leukemia (AML) patients. Complications associated with CVCs are frequently encountered and contribute to morbidity and mortality. Prospective studies investigating...
8.
9.
Patel A, Agha M, Raptis A, Hou J, Farah R, Redner R, et al.
Oncol Res
. 2020 Aug;
28(7):811-814.
PMID: 32753091
Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with...
10.
Redner R, Beumer J, Kropf P, Agha M, Boyiadzis M, Dorritie K, et al.
Leuk Lymphoma
. 2018 Apr;
59(11):2595-2601.
PMID: 29616864
Src family kinases (SFKs) are hyperactivated in acute myeloid leukemia (AML). SFKs impede the retinoic acid receptor, and SFK inhibitors enhance all-trans retinoic acid (ATRA)-mediated cellular differentiation in AML cell...